Abstract:Myasthenia gravis (MG) is a rare, treatable, antibody-mediated disease characterized by fatigable muscle weakness of extraocular muscles (EOMs) and non-ocular skeletal muscles. The antibodies are directed against muscle-endplate proteins, most frequently the acetylcholine receptor (AChR) alpha-subunit. Although most MG patients respond to immunosuppressive treatment, some individuals, frequently with African-genetic ancestry, develop treatment-resistant ophthalmoplegia (OP-MG). Although the underlying pathogenetic mechanisms of OP-MG remain unknown, experimental rodent models of MG showed upregulation of genes involved in oxidative metabolism in muscles. EOMs are highly dependent on oxidative metabolism. We opportunistically sampled EOM-tendons of two rare OP-MG patients (and non-MG controls) undergoing re-alignment surgery, and established ocular fibroblast cultures. Metabolic assays were performed on these live cells to assess real-time differences in energy metabolism. To study the cellular bioenergetic profiles in the context of MG, we exposed the cultures to homologous 5% MG sera for 24 h, vs. growth media, from two independent MG patients (with circulating AChR-antibodies) and five controls without MG, and estimated the fold change in oxygen consumption rates in response to three compounds which inhibit different mitochondrial chain complexes. Quantitative PCR (qPCR) was performed in cells before and after MG sera exposure, to assess transcript levels of mitochondrial genes, PDK4, ANGPTL4 and UCP3, which were altered in experimental MG. In response to the mitochondrial stressors, basal oxidative metabolism parameters were similar between OP-MG and control fibroblasts (p = 0.81). However, after exposure to MG sera, bioenergetic parameters (oxygen consumption rate as an indicator of oxidative phosphorylation; extracellular acidification rate as an indicator of glycolysis), were induced to higher levels in OP-MG fibroblasts compared to controls (2.6-fold vs 1.5-fold; p = 0.031) without evidence of mitochondrial insufficiency in the OP-MG ocular fibroblasts. In support of the bioenergetic responses to the same MG sera, gene transcripts of PDK4 and ANGPLT4 in ocular fibroblasts also showed significant upregulation (p ≤ 0.041), but similarly in OP-MG and control cases. Taken together we showed similar basal and metabolic adaptive responses after exposure to mitochondrial inhibitors in ocular fibroblasts derived from OP-MG cases and controls, although the OP-MG cells showed greater activation in response to MG conditions. These pilot results in orbital-derived tissues provide support for myasthenic-induced changes in cellular metabolism and evidence that orbital fibroblasts may be useful for dynamic bioenergetic assessments.

The Problem of Squarable Lunes

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Increase of circulating CD4 +CD25 + T cells in myasthenia gravis patients with stability and thymectomy

Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis

Effect of Follicular T Helper and T Helper 17 Cells-Related Molecules on Disease Severity in Patients with Myasthenia Gravis

Rhizosphere soil nitrogenase (C2H2 reduction) as influenced by plant density in intermediate deep water rice

Mitochondrial bioenergetics in ocular fibroblasts of two myasthenia gravis cases

A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression

Dynamic study of circulating CD_4~+CD_(25)~(high) T cells in myasthenia gravis

Augmentation Of Circulating Follicular Helper T Cells And Their Impact On Autoreactive B Cells In Myasthenia Gravis

In vitro modulation of T cells in myasthenia gravis by low-dose IL-2

Electrophysiological Insights: Using Repetitive Nerve Stimulation to Monitor Clinical Status and Remission in Myasthenia Gravis

New treatment strategies in Myasthenia gravis

Onwards and Upwards: Why Companies Change Their Executive Remuneration Schemes, and Why this Leads to Increases in Pay

The Change and Relevant Significance of Th1/Th2/Th17 Cytokines in Myasthenia Gravis

[Effects of corticosterone on the activity of the neurons in the rostral ventrolateral medulla of rats].

Myasthenia Gravis: T and B Cell Reactivities to the Β-Bungarotoxin Binding Protein Presynaptic Membrane Receptor

[Timolol and dapiprazole combination in patients with glaucoma].

Serum Metabolomic Profile of Myasthenia Gravis and Potential Values As Biomarkers in Disease Monitoring

Circulating Regulatory T Cells and B Cell-Activating Factor Receptor on B Cells in Patients with Myasthenia Gravis

Decoding myasthenia gravis: advanced diagnosis with infrared spectroscopy and machine learning